Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575148 | 0.78 | HTR7 (0.53) | NTRK1JAK2JAK3HTR7EGFR | |
| SCHEMBL20575147 | 0.78 | HTR7 (0.53) | NTRK1JAK2JAK3HTR7EGFR | |
| SCHEMBL27738470 | 0.75 | NTRK1 (0.48) | NTRK1CCNT1CDK9CDK2JAK2 | |
| SCHEMBL13663410 | 0.75 | FAAH (0.62) | FAAH | |
| SCHEMBL4292012 | 0.75 | FAAH (0.62) | FAAH | |
| SCHEMBL22535401 | 0.71 | NTRK1 (0.65) | NTRK1JAK2JAK3 | |
| SCHEMBL22328022 | 0.69 | NPC1 (0.64) | EGFRERBB3 | |
| SCHEMBL2866283 | 0.69 | CDK5 (0.42) | CCNT1CDK9CDK2 | |
| SCHEMBL4619629 | 0.69 | NTRK1 (0.58) | NTRK1CCNT1CDK9CDK2CCNC | |
| SCHEMBL14670569 | 0.69 | NTRK1 (0.58) | NTRK1CCNT1CDK9CDK2CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180346450-A1 | TRK INHIBITION | NANTBIO, INC. | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346450-A1 | TRK INHIBITION | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885CCNT1 2403/4885CDK9 966/4885 |
| US-10800760-B2 | Trk inhibition | NTRK1, NTRK3, NTRK2 | NTRK1 1/4885CCNT1 2403/4885CDK9 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.